Juveacell, Rejuran, and Juvelook are not interchangeable: Juveacell delivers a pre-formed hADM scaffold for fibroblasts to populate, Rejuran delivers polynucleotide signals to stimulate endogenous collagen synthesis, and Juvelook combines PDLLA microspheres with HA for sustained biostimulation plus immediate hydration. The right choice depends on individual skin goals—texture refinement, cellular repair signaling, or longer-duration collagen induction—rather than a universal efficacy ranking, as no head-to-head RCT comparing all three currently exists.
Juveacell, Rejuran, and Juvelook are all described as regenerative skin boosters, but they work through fundamentally different mechanisms rather than being interchangeable versions of the same treatment. Juveacell delivers a pre-formed extracellular matrix (ECM) scaffold derived from human acellular dermal matrix (hADM), Rejuran delivers polynucleotides (PN) that signal the skin's own cells to produce collagen, and Juvelook delivers poly-D,L-lactic acid (PDLLA) microspheres combined with hyaluronic acid to stimulate sustained collagen production over time cococlinic.kr. Understanding these distinctions at the ingredient level is the most useful starting point for any consultation conversation. It is also important to note that no head-to-head randomized controlled trial comparing all three products has been identified in the available evidence base, so the comparison that follows rests on mechanism descriptions, formulation characteristics, and small-scale or preclinical data rather than direct efficacy rankings.
COCO Clinic offers all three, and a professional consultant helps patients identify which approach aligns with their individual skin condition and goals before any procedure is planned.
What Is Juveacell? The hADM Scaffold Concept Explained
Human acellular dermal matrix (hADM) is donated human dermis from which all living cells have been removed, leaving behind a preserved structural scaffold of collagen, elastin, and glycosaminoglycans (GAGs) cococlinic.kr. Juveacell is an ADM-derived product that retains this collagen, elastin, and ECM architecture, positioning it as a material that provides structural support rather than simply triggering a biological signal. When injected into the dermis, this scaffold is intended to give the skin's own fibroblasts a framework into which they can migrate and deposit new collagen.
Juveacell's manufacturing process uses supercritical CO₂ decellularization — a surfactant-free method described by the manufacturer as minimizing ECM structural damage and chemical residue compared with detergent-based processes cococlinic.kr. A 2024 preclinical study by Giang et al. reported reduced inflammatory signaling and fibroblast infiltration with new collagen formation in supercritical CO₂-decellularized dermal matrix, though this work was conducted in an animal model and cannot be directly extrapolated to human clinical outcomes cococlinic.kr. The supercritical CO₂ characteristic is a manufacturer-described feature, and independent comparative data on this processing method remain limited.
At COCO Clinic, Juveacell is used in two formats: the 8% formulation for the under-eye area, placed with a cannula, and Juveacell V for full-face skin regeneration. Which one is chosen depends on the area and on what the skin is short of.
At COCO Clinic, concentration selection is part of the pre-treatment assessment process, and the appropriate format is determined based on the individual patient's skin condition and goals rather than a fixed protocol.
How Rejuran Works: Polynucleotide Signaling Rather Than Structural Delivery
Rejuran's active ingredient is polynucleotides (PN) derived from salmon DNA. Rather than supplying a pre-formed structural material, PN acts as a biological signal that stimulates fibroblast activity and encourages the skin's own cells to synthesize collagen endogenously. It is a course rather than a single treatment: 3 to 4 sessions 4 to 6 weeks apart, with most people noticing the change from the second or third. Numbing cream is applied beforehand. Small bumps at the injection points and some redness settle over one to two weeks, and a fish allergy must be disclosed before treatment.
The mechanistic contrast with Juveacell is meaningful for setting expectations. Rejuran asks the skin's own cells to produce collagen in response to a molecular signal; Juveacell provides a matrix into which fibroblasts can migrate and deposit new collagen cococlinic.kr. Both approaches aim to improve skin density and elasticity, but the timeline, depth of effect, and patient experience may differ depending on skin condition, injection technique, and dosage. Neither approach should be considered universally superior — the difference is one of mechanism and intended application, not a hierarchy of efficacy.
How Juvelook Works: PDLLA Biostimulation and Dual-Action Collagen Induction
Juvelook combines PDLLA microspheres with hyaluronic acid to deliver what is described as a dual-action effect: the HA component provides an immediate hydration benefit, while the PDLLA microspheres degrade gradually in the dermis, triggering a controlled fibroblast response and sustained collagen production over time. This dual timeline — immediate hydration followed by a building biostimulatory effect — is a distinguishing feature of the PDLLA class of skin boosters.
The PDLLA component works by provoking a mild foreign-body response that drives collagen synthesis. As the PDLLA effect builds over weeks to months, the initial HA hydration effect fades, meaning the full benefit of the treatment is realized progressively rather than immediately. Based on currently available clinic-sourced data, Juvelook (PDLLA) is associated with an effect duration of approximately 12 months, compared with 3–6 months for Juveacell (hADM) — though these figures originate from first-party sources and individual variation is expected cococlinic.kr.
Juvelook should also be distinguished from Sculptra, which uses a different lactic acid isomer (PLLA) and is typically associated with more pronounced volumizing effects. Juvelook is positioned for texture improvement and collagen quality rather than dramatic volume augmentation; where the main goal is volume, a filler or a volume-oriented collagen booster such as Radiesse is the more direct route.
COCO Clinic's professional consultant can explain how Juvelook's dual-action timeline compares with Juveacell when patients are weighing treatment frequency against duration of effect, helping to frame the decision around realistic expectations rather than marketing claims.
Evaluation Axes: Comparing the Three Approaches Across Key Clinical Dimensions
Organizing the comparison across concrete clinical dimensions helps clarify what each product is and is not designed to do.
Active mechanism. Juveacell delivers an ECM scaffold that fibroblasts can populate; Rejuran delivers PN/PDRN biological signals that stimulate endogenous collagen synthesis; Juvelook delivers PDLLA biostimulation combined with HA hydration cococlinic.kr. These are genuinely different strategies, not variations on a single theme.
Primary skin target. Juveacell (hADM) is considered where the skin is short on structure to begin with — thin, delicate areas such as under the eyes and the neck. Rejuran's PN signaling is oriented toward texture, fine lines and redness. Juvelook's PDLLA component targets thickness and density — pores, scars and firmness — over a longer horizon.
Reported duration of effect. Juveacell (hADM) is associated with a reported duration of 3–6 months, and Juvelook (PDLLA) with approximately 12 months cococlinic.kr. No comparable duration figure for Rejuran is present in the verified evidence base and is therefore not stated here. All duration figures should be understood as reported ranges rather than guaranteed outcomes.
Typical downtime and recovery. Across all three, patients should expect temporary swelling, redness, and bruising at injection sites. With Juveacell, mild swelling or bruising usually settles within 2 to 3 days; allow up to 1 to 2 weeks. With Rejuran, small bumps at the injection points settle over one to two weeks. Juveacell has not formed nodules in our experience; with PDLLA products a small lump is occasionally possible and usually improves with massage.
Strength of current clinical evidence. A small split-face pilot study of 20 participants observed improvements in skin density, elasticity, wrinkle, and hydration markers over 20 weeks in the hADM-treated side cococlinic.kr. The Giang et al. (2024) preclinical findings on supercritical CO₂-decellularized dermal matrix were conducted in an animal model cococlinic.kr. Facial injection studies across all three product categories remain small-scale and short-term in follow-up, which limits the strength of conclusions that can be drawn from the current evidence base cococlinic.kr.
Limitations and Evidence Gaps Across All Three Products
No large-scale, long-term, head-to-head randomized controlled trial comparing Juveacell, Rejuran, and Juvelook has been identified in the available evidence. The comparison presented in this article is based on mechanism descriptions, small pilot studies, and preclinical data — a foundation that is informative but not definitive.
The 20-participant split-face study supporting hADM outcomes is explicitly a small-scale pilot, and its results may not generalize across different skin types, ages, or treatment areas cococlinic.kr. The Giang et al. (2024) preclinical findings were conducted in an animal model and cannot be directly extrapolated to human clinical outcomes cococlinic.kr. Duration-of-effect figures — 3–6 months for Juveacell and approximately 12 months for Juvelook — originate from first-party or clinic-sourced materials and may reflect optimal conditions rather than the average patient experience cococlinic.kr.
The term "regenerative" is applied loosely across all three product categories in marketing and clinical contexts alike. The distinction between supplying structural material (hADM), triggering a biological signaling response (PN), and provoking a controlled foreign-body reaction (PDLLA) is clinically meaningful for managing expectations, but it does not translate into a simple ranking of effectiveness.
Because evidence for all three products is still maturing, COCO Clinic's approach is to discuss the current state of the evidence transparently during consultation, so patients can make informed decisions based on mechanism and realistic expectations rather than marketing claims alone.
Practical Selection Considerations: Matching Goals to Mechanism
The most useful framework for choosing among these three approaches is goal-to-mechanism matching rather than product ranking. Where the skin is short on structure — thin, delicate areas such as under the eyes and the neck — Juveacell (hADM) is the one to discuss. Where the concern is texture, fine lines or redness, the condition of the skin itself, PN (Rejuran) is the closer fit. Where the concern is thickness and density — pores, scars, firmness — PDLLA (Juvelook) is the one to discuss.
ADM-class boosters are better suited to natural texture and elasticity improvement than to dramatic volume augmentation. Where volume itself is the goal, a filler or a volume-oriented collagen booster such as Radiesse is the more direct route. This does not make ADM-class products inferior — it reflects a difference in what each product category is designed to achieve.
Injection accuracy, concentration, and dosage are as important as product selection in determining outcomes, and this principle applies equally to all three products. Skin type, baseline collagen density, age, and prior treatment history all influence which approach a clinician is likely to recommend, and none of these factors can be assessed without an in-person evaluation.
At COCO Clinic, a professional consultant provides a detailed one-on-one consultation, and the doctor may also conduct a brief assessment before the procedure, to help determine whether Juveacell or another regenerative option is appropriate for the individual patient's skin condition.
Safety Profile and Post-Treatment Considerations
Common post-treatment effects shared across injectable skin boosters include temporary swelling, redness and bruising at injection sites. With Rejuran, small bumps at the injection points are normal and settle over one to two weeks; with Juveacell, swelling or bruising usually settles within 2 to 3 days, and up to 1 to 2 weeks for some people. These effects are generally expected and self-limiting, but patients should follow post-procedure guidance from their treating clinician.
Certain symptoms after any of these treatments warrant prompt clinical attention: increasing pain, extensive redness or swelling, discharge or pus, severe itching, or the development of a firm nodule accompanied by skin color change. These warning signs should not be managed with self-care alone.
With PDLLA products such as Juvelook, a small lump is occasionally possible; it usually improves with massage, and the clinic provides additional care if needed. Juveacell has not formed nodules in our experience. Patients considering any of these treatments should discuss their individual risk profile with a clinician before proceeding.
Precautions differ by product: after Juveacell, avoid saunas and prolonged heat for about a week; after Juvelook, avoid sauna, strenuous exercise and heavy drinking for one to two weeks, and massage the area as instructed for the first few days to keep the particles evenly spread. Follow the treating clinician's specific aftercare instructions.
COCO Clinic provides post-treatment guidance specific to the product and concentration used, and patients are encouraged to contact the clinic if they experience any unexpected symptoms after their procedure.
Frequently Asked Questions
Is Juveacell better than Rejuran or Juvelook?
No single product is universally superior. Juveacell, Rejuran, and Juvelook work through different mechanisms — ECM scaffold delivery, polynucleotide signaling, and PDLLA biostimulation respectively — and the most appropriate choice depends on individual skin condition, treatment goals, and a clinician's assessment rather than a general ranking cococlinic.kr.
How long does Juveacell last compared with Juvelook?
Based on currently available clinic-sourced data, Juveacell (hADM) is associated with an effect duration of approximately 3–6 months, while Juvelook (PDLLA) is associated with approximately 12 months; however, these figures reflect reported ranges rather than guaranteed outcomes, and individual results vary depending on skin condition, dosage, and injection technique cococlinic.kr.
What does "acellular dermal matrix" mean in the context of a skin booster?
Acellular dermal matrix (ADM) refers to donated human dermis from which all living cells have been removed, leaving behind a preserved structural scaffold of collagen, elastin, and glycosaminoglycans; when injected, this scaffold is intended to provide a framework into which the skin's own fibroblasts can migrate and deposit new collagen cococlinic.kr.
Can Juveacell, Rejuran, and Juvelook be combined?
Combination protocols are used in clinical practice, but whether combining these products is appropriate for a specific patient depends on skin condition, treatment history, and the clinician's judgment; patients should discuss combination options directly with their treating physician rather than relying on general guidance.
Where can I get Juveacell in Seoul?
COCO Clinic, located in Gangdong-gu, Seoul near Cheonho Station, offers Juveacell, Rejuran and Juvelook; a professional consultant can provide a detailed one-on-one consultation to assess whether Juveacell or another option is suitable based on your individual skin condition and goals.
References
- [1] Polynucleotides in esthetic medicine: systematic review — PubMed
- [2] Juveacell hADM regeneration overview — COCO Clinic